A high-throughput LC–MS method using core-shell UHPLC columns to screen for a panel of 11 drugs of abuse (expanded SAMHSA) was developed. The corresponding SPE method allowed the reproducible separation and quantitation of these 11 components in less than 2 min. This method demonstrates the power of new-generation HPLC media as well as some of the factors one must consider when developing such methods for LC–MS analysis.
Fast turnaround time is critical in the clinical testing environment. Here, fast liquid chromatography (LC) technologies were utilized for the comprehensive assay of commonly prescribed pain management drugs in under 2 min. The use of fast LC also provided significantly improved sensitivity. A mini-validation for these analytes in human urine was performed and acceptable values for accuracy, precision, linearity, lot-to-lot variability, and matrix effects were demonstrated for each analyte.
Adapting the use of "ultrahigh" performance chromatography for liquid chromatography–mass spectrometry (LC–MS) applications requires specific considerations in integrating the instrument platforms. Mobile phase options are limited to volatile buffers, and slow MS sampling rates can limit throughput advantages that such next-generation media offer. High-throughput LC–MS methods of different relevant pharmaceutical and environmental mixtures were developed using ultrahigh performance core-shell media. Such methods were developed using standard HPLC systems and back pressures, showing the ease and utility of using core-shell media for increasing throughput of LC–MS methods.
The analysis of polar compounds in support of clinical and preclinical pharmacokinetic studies requires an analytical methodology capable of achieving ultra-low detection and quantification limits. The high sensitivity afforded by coupling HPLC with tandem mass spectrometry (MS-MS) has made it the technique of choice in this environment, but it is subject to the following limitations when reversed phase liquid chromatography (RPLC) is used: